Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent van der Noort

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Cancer|January 3, 2014
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentSushil Badrising, Vincent van der Noort, Inge M van Oort, et al.
The Journal of Pathology. Clinical Research|October 28, 2016
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancerWillemijn Sme Theelen, Lorenza Mittempergher, Stefan M Willems, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|January 18, 2018
Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society auditLiset Lansaat, Vincent van der Noort, Simone E Bernard, et al.
JAMA Oncology|May 16, 2026
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical TrialJules Lansu, Judith V M G Bovée, Pètra M Braam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 StudyDirk De Ruysscher, Anne-Marie C Dingemans, John Praag, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 7, 2021
Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trialsWillem J A Witlox, Bram L T Ramaekers, Benjamin Lacas, et al.
Breast (Edinburgh, Scotland)|February 15, 2025
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocolAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2024
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery ProtocolJade M van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, et al.
JAMA Oncology|August 28, 2025
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast CancerAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Cancer|January 3, 2014
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentSushil Badrising, Vincent van der Noort, Inge M van Oort, et al.
The Journal of Pathology. Clinical Research|October 28, 2016
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancerWillemijn Sme Theelen, Lorenza Mittempergher, Stefan M Willems, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|January 18, 2018
Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society auditLiset Lansaat, Vincent van der Noort, Simone E Bernard, et al.
JAMA Oncology|May 16, 2026
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical TrialJules Lansu, Judith V M G Bovée, Pètra M Braam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 StudyDirk De Ruysscher, Anne-Marie C Dingemans, John Praag, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 7, 2021
Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trialsWillem J A Witlox, Bram L T Ramaekers, Benjamin Lacas, et al.
Breast (Edinburgh, Scotland)|February 15, 2025
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocolAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2024
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery ProtocolJade M van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, et al.
JAMA Oncology|August 28, 2025
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast CancerAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Pageof 11